ArticleBiomedicines2022

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer.

Raquibul Hannan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.